The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.
The team said that by understanding why some members of this family don't feel pain, they could unearth new drug targets to treat others with chronic pain.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The one-year partnership will focus on identifying patients with abnormal pain conditions and validating the genetic findings as potential targets for drugs.
Smaller labs, hospital outreach labs, and labs servicing high numbers of elderly are thought to face the highest risks.
The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.
The firm has yet to publish peer-reviewed clinical evaluations, and genetics experts have raised doubts about its choice of targets to predict addiction.
The companies plan to combine their platforms and research to launch new clinical assays and develop procedures and therapeutics to treat pain.
In Nature this week: short tandem repeats contribute to gene expression variation in humans, mutation linked to cold-aggravated peripheral pain, and more.
The effort has provided a comprehensive view of the toxin proteins involved in the sting of these dangerous jellyfish, which is now being used to identify targets for inhibitory drugs.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.